Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.

Zhao, Ming; Scott, Stephen; Evans, Kurt W; Yuca, Erkan; Saridogan, Turcin; Zheng, Xiaofeng; Wang, Heping; Korkut, Anil; Cruz Pico, Christian X; Demirhan, Mehmet; Kirby, Bryce; Kopetz, Scott; Diala, Irmina; Lalani, Alshad S; Piha-Paul, Sarina; Meric-Bernstam, Funda

Zhao, Ming; Scott, Stephen; Evans, Kurt W; Yuca, Erkan; Saridogan, Turcin; Zheng, Xiaofeng; Wang, Heping; Korkut, Anil; Cruz Pico, Christian X; Demirhan, Mehmet; Kirby, Bryce; Kopetz, Scott; Diala, Irmina; Lalani, Alshad S; Piha-Paul, Sarina; Meric-Bernstam, Funda.

Afiliación

Zhao M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Scott S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Evans KW; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yuca E; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Saridogan T; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zheng X; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wang H; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Korkut A; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cruz Pico CX; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Demirhan M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kirby B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Diala I; Puma Biotechnology Inc, Los Angeles, California.
Lalani AS; Puma Biotechnology Inc, Los Angeles, California.
Piha-Paul S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. fmeric@mdanderson.org.

Clin Cancer Res ; 27(6): 1681-1694, 2021 03 15.

Article en En | MEDLINE | ID: mdl-33414137

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica/farmacología; Biomarcadores de Tumor/antagonistas & inhibidores; Neoplasias de la Mama/tratamiento farmacológico; Neoplasias Colorrectales/tratamiento farmacológico; Neoplasias Esofágicas/tratamiento farmacológico; Regulación Neoplásica de la Expresión Génica/efectos de los fármacos; Receptor ErbB-2/metabolismo; Animales; Apoptosis; Biomarcadores de Tumor/genética; Biomarcadores de Tumor/metabolismo; Neoplasias de la Mama/metabolismo; Neoplasias de la Mama/patología; Proliferación Celular; Neoplasias Colorrectales/metabolismo; Neoplasias Colorrectales/patología; Quinasa 4 Dependiente de la Ciclina/antagonistas & inhibidores; Quinasa 6 Dependiente de la Ciclina/antagonistas & inhibidores; Neoplasias Esofágicas/metabolismo; Neoplasias Esofágicas/patología; Everolimus/administración & dosificación; Femenino; Humanos; MAP Quinasa Quinasa 1/antagonistas & inhibidores; Ratones; Ratones Endogámicos NOD; Ratones Desnudos; Ratones SCID; Piperazinas/administración & dosificación; Inhibidores de Proteínas Quinasas/farmacología; Pirazoles/administración & dosificación; Piridinas/administración & dosificación; Piridonas/administración & dosificación; Pirimidinas/administración & dosificación; Pirimidinonas/administración & dosificación; Quinolinas/administración & dosificación; Serina-Treonina Quinasas TOR/antagonistas & inhibidores; Células Tumorales Cultivadas; Ensayos Antitumor por Modelo de Xenoinjerto

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias Esofágicas / Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Regulación Neoplásica de la Expresión Génica / Receptor ErbB-2 Tipo de estudio: Prognostic_studies Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google